Exosome Diagnostics, Inc., a developer of revolutionary biofluid - based molecular diagnostics, announced the recent JAMA Oncology publication of a prospective clinical evaluation study for the company’s novel urine -based prostate cancer liquid biopsy test, ExoDxTM Prostate (IntelliScore).Topline results from the study were first presented in a late -breaking plenary session at the American Urological Association (AUA) Annual Meeting in May, 2015. Exosome Diagnostics plans to launch this first-of-its-kind RNA-based test in its CLIA lab in the second quarter of 2016.